Phase II Trial of Continuation Therapy in Advanced NSCLC

NCT03083808 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Non-Small-Cell Lung Cancer

Interventions

DRUG: Pembrolizumab

Sponsor

Greg Durm, MD

Collaborators

[object Object]
[object Object]